ISSN: 1859 - 2872
Treatment for advanced stage pulmonary adenocarcinoma EGFR mutations positive by gefitinib
Main Article Content
Keywords
Abstract
Summary
Objective: To evaluate the result of treatment for advanced stage pulmonary adenocarcinoma patients who have EGFR mutations by gefitinib. Subject and method: A prospective study and follow up, 118 advanced stage pulmonary adenocarcinoma patients with EGFR mutations were treated by gefitinib, they were followed and evaluated each 3 months or when they have symptoms of progressive disease. The main criterias response were progressive free disease and the overall response rate. The second criterias response were overall survival, disease control rate, the ratio of survival after 12 months, 24 months, 36 months, 48 months, 60 months of treatment and the toxicity. Result: The mean of tracking time was 19.42 months, at 6 months after treatment, the percentage of complete response was 16.1%, partial response 63.6%, stable disease 6.8%, progressive disease 13.5%, the overall response rate was 79.7% and the disease control rate was 86.5%. The median PFS was 15 ± 0.75 months and the median OS was 32 ± 1.39 months. The ratio of OS after 12 months was 83.9%, 24 months 35.6%, 36 months 11%, 48 months 3.4%, as for 60 months was 1.7%. The adverse events met in 62.7% of patients, in which, 51.7% of patients was rash and acne, but most of all was level 1 and 2. Conclusion: Gefitinib was the first generation TKI that has good effective in advanced stage pulmonary adenocarcinoma patients with EGFR mutations.
Keywords: Adenocarcinoma, EGFR mutations, gefitinib.
Article Details
References
2. Nguyễn Minh Hà, Trần Huy Thịnh, Trần Vân Khánh (2014) Erlotinid bước một trên bệnh nhân ung thư phổi không tế bào nhỏ giai đoạn muộn có đột biến gen EGFR. Tạp chí Nghiên cứu Y học, phụ chương 91(5), tr. 6-12.
3. WHO (2018) GLOBOCAN 2018 - Lung cancer.
4. NCCN Guideline Insights, Non - Small Cell Lung Cancer, version 1.2020, feature updates to the NCCN Guidelines.
5. Mok TS, Wu YL, Thongprasert S et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Eng J Med 361(10): 947-958.
6. Maemondo M, Inoue A, Kobayashi K et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362: 2380-2388.
7. Tomohiro T, Koichi K, Kensuke N et al (2015) Speccific organ metastase and survival in metastatic non-small cell lung cancer. Molecular and clinical oncology 3: 217-221.
8. Wenting N, Wenxing C, Yin L (2018) Emerging finding into molecular mechanism of brain metastase. Cancer Medicine 7: 3820-3833.
9. Devarati M, Yu-Hui C, Richard L et al (2019) EGFR mutant locally advanced non-small cell lung cancer is at increased risk of brain metastasis. Clinical and Translational Radiation Oncology 18: 32-38.
10. Yuichiro O, Fumio I, Kazuhiko N et al (2019) Osimetinib versus standard-of- care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset. Japanese journal of clinical oncology 49(1): 29-36.
Article Sidebar
